What's New in Research Funding

Page last updated April 19, 2018.

We are pleased to assist the research community in identifying potential sources of funding through the provision of information posted here:

  • All Applicants submitting through the University of Toronto MUST have submitted their application information online via the My Research Applications (MRA) portal. This is an online submission process to obtain institutional approval on research applications. Please note that you will be required to upload a copy of the application to this online submission. Please complete this step as early as possible and at least several days ahead of the deadline to insure all approvals are obtained on time. Please visit the OVPRI's MRA webpage for complete information on this process.
  • Please note, all grants requiring the Dean's signature should be brought to the Faculty of Medicine Research Office in the Medical Sciences Building, Room 2331 to the attention of Cindy Faber cindy.faber@utoronto.ca.
  • Also, our office offers a grant editing service for researchers submitting proposals to tri-council or any other funding agency. For more information, please contact dan.harney@utoronto.ca.
  • Recently received news and updates are posted below and sent via email to our LISTSERV. To join click here.

Comprehensive funding opportunities may be searched through these links:

Recently Received News and Updates:

Join in U of T’s advocacy efforts as we urge the federal government to implement all of the Fundamental Science Review Report’s recommendations. Get involved today and #supportthereport by phoning or writing your MP, sending a postcard to Ottawa, or making your support for research known on social media.

April 19, 2018

  • U of T - University of Manchester joint workshop on collaborative opportunities in biomaterials and regenerative medicine. The University is pleased to invite those interested to participate in an exploratory workshop on potential areas of collaboration in biomaterials and regenerative medicine with the University of Manchester. The session will be led by Professor Chris Yip, Institute of Biomaterials & Biomedical Engineering & Associate Vice-President, International Partnerships at U of T and Professor Sarah Cartmell, Lead, School of Materials from University of Manchester. The launch of a collaborative fund for joint projects between University of Manchester and U of T will be announced on the morning of April 24th and will conclude the formal component of this workshop. Complete agenda and RSVP information can be found here.
    Date: April 23 & 24, 9am - 5pm. 
    Location: Wallberg Building, Room 215 (St. George Campus)
  • Genome Canada: Genomic Applications Partnerships Program (GAPP) Round 12The GAPP funds public-private research collaborations focused on developing genomics-derived technologies that address opportunities and challenges identified by industry, government, not-for-profits or other "receptors" of genomics knowledge and tools. Please note that the GAPP is a rolling program, and is currently in Round 12. Applicants interested in applying to the GAPP Round 12 are encouraged to contact Shobha Ramsubir at Ontario Genomics. Key Paremeters of the Program: Maximum project size: $300K - $6M (total); Co-funding: 1/3 investment from Genome Canada (max), 1/3 investment from Receptor (min) and 1/3 of other applicant-identified co-funding; Project Stage: downstream R&D/validation/pilot; Project Term: 1-3 years. Draft EOIs are due to RSO and Ontario Genomics on May 2, 2018.
    To learn more please visit the GAPP homepage, or the UofT funding opportunity.

  • NSERC Strategic Partnership Grants for Projects - NSERC Webinars for full applications. NSERC will host webinar sessions regarding the 2018 competition for Strategic Partnership Grants for Projects. The webinar will discuss the preparation of a Full Application. Full Applications may be submitted by applicants invited forwards by NSERC from the Letter of Intent stage. 
    English: Wednesday, April 25 at 12:30 pm ET, and Tuesday, May 1 at 12:30pm ET.
  • Canadian Cancer Society and the Chordoma Foundation: Chordoma Research Grants.  As a result of a fundraising partnership with the Chordoma Foundation and generous donors, there is funding available to support up to 2 meritorious applications that will impact our understanding of chordoma and generate new ideas leading to critically needed systemic therapies. It is hoped that this grant award will utilize innovative technologies and foster new collaborations in order to drive translational research findings rapidly to the clinic. Applications that build new collaborations and capacity in chordoma research are encouraged. Grant budgets may be up to $100,000 per year and a maximum of $150,000 per grant over a 2-year period, and will be non-renewable. Deadline for abstract registrations: May 1, 2018.
  • Alex's Lemonade Stand Foundation for Childhood Cancer: Grants and Awards. 
    • Reach Grants are designed to move hypothesis-driven research into the clinic. The $250,000, two year grant is intended to fund developmental therapeutic studies in the late stage of preclinical testing. A successful application will identify an unmet clinical need relevant to the care of pediatric patients with cancer and describe how the work performed will allow for the translation to the clinic within two years of completion. A plan and timeline for clinical testing and trial implementation is expected. This grant does not fund clinical trial expenses. Deadline for applications: May 21, 2018.
    • The ‘A’ Award is a four-year grant designed for the early independent career scientist who wants to establish a career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. The award amount is now a maximum of $200,000 per year with the possibility of additional funding in a 5th year. Deadline for applications: May 21, 2018.
  • National Multiple Sclerosis Society: Pilot Research Grants. The Society funds high-risk pilot grants to quickly test novel ideas. Funding is provided for one year to test innovative, cutting-edge ideas or untested methods, and to gather sufficient preliminary data to apply for longer-term funding. We welcome applications for studies related to multiple sclerosis that may serve to advance our mission of stopping MS progression, restoring function and improving quality of life, and preventing MS. The Society supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care and rehabilitation. The maximum amount is $50,000 for one year. Deadline for pre-applications is May 7, 2018, and full applications are due on May 9, 2018.
  • The Champ Foundation: Call for Proposals for Pearson Syndrome. The Champ Foundation supports research toward better treatment and a cure for diseases caused by mitochondrial DNA deletions, namely Pearson Syndrome. They are releasing a call for proposals to find and fund the most innovative research projects aligned with this mission. Deadline for proposals: May 25, 2018.
  • The Hope Foundation: SWOG Early Exploration and Development (SEED) Fund. SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the NCTN. These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. Amount: $50,000 USD over 1 or 2 years. Deadline for applications: July 1, 2018.
  • NIH: Various Opportunities. Unless otherwise stated in the funding opportunity, see Standard Due Dates Schedule for deadlines for each Grant category. If you intend to apply via the University of Toronto, it is recommended you contact Krista Montgomery in Research Services at least two weeks prior to submitting an NOI or application.  For more information on NIH application and the submission process, please visit the University's Research Funding Opportunities found here.
    • Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R21) and (R01)
    • Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01) and (R21)
    • Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21) and (R01)
    • Research on the Health of Transgender and Gender Nonconforming Populations (R21) and (R01)
    • Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries (R21)
    • Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03)
    • Impact of Initial Influenza Exposure on Immunity in Infants (U01)
    • Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01)
    • Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01)
    • Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01) and (R21)
    • Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21)
    • Investigator-Initiated Genomic Medicine Research (R01) and (R21)
    • Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33)
    • Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21)
    • Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21)
    • Next-Generation Biologics for Sustained HIV Remission (R01)
    • Development of a virtual bioequivalence trial simulation platform that integrates population pharmacokinetic modeling algorithms into physiologically-based pharmacokinetic models (U01)
    • Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01) and (R21)

April 4, 2018

  • Banting & Best Diabetes Centre (BBDC)/Heart & Stroke Richard Lewar Centre of Excellence (HSRLCE): 2018 Pilot and Feasibility Grant in Cardiovascular and Diabetes Research. The Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research (HSRLCE) and the Banting & Best Diabetes Centre (BBDC) in conjunction with the Vice-Dean, Research and Innovation, Faculty of Medicine, are pleased to announce the 2018 Pilot and Feasibility Grant in Cardiovascular and Diabetes Research competition. This competition is now open to both basic science and clinical research applications. All applicants and co-applicants must be members of either the BBDC or the HSRLCE. Further, principal applicants must have at least one co-applicant who is a member of a different Centre (e.g. if the PI is a member of HSRLCE, at least one co-applicant must be a member of the BBDC). Deadline for applications: May 18, 2018 at 4pm.
  • The Centre for Aging + Brain Health Innovation (CABHI): 2018 Call for Innovations: Industry Innovation Partnership Program – Round 3. CABHI's mission is to accelerate the development, validation, commercialization, dissemination and adoption of innovative products, services and best practices to support brain health and aging. The Researcher-Clinician Partnership Program (RCP2) will support teams of clinicians and researchers collaborating to refine, test, validate and disseminate innovative solutions in real-world settings. Solutions must be at an advanced stage of development, with promising scalability. Organizations of successful applicants will receive up to $500,000 (CAD) to support their projects. Projects cannot exceed 15 months in duration (including submission of final project report to CABHI) and must begin by August 2018. 
    INFORMATION WEBINARS: Friday, April 13 from 1pm - 2pm EDT; or Friday, April 27, from 1pm -2pm EDT. Register here.
    UofT internal deadline: May 11, 2018; Sponsor deadline: May 18, 2018.
  • PRE-ANNOUNCEMENT: CIHR/NSERC/SSHRC - Collaborative Health Research Projects (CHRP) with a Special Call: Artificial Intelligence, Health and Society. The CHRP initiative supports innovative, interdisciplinary, collaborative research projects, requiring participation from the natural sciences or engineering community together with the health sciences community. This initiative focuses on the translation of the research results to knowledge/technology users (KTUs) and related stakeholders outside the academic or training environment. The research intersection chosen for this Special Call is Artificial Intelligence (AI), Health and Society. Given the pace of technological advancement, the scope of potential uses of AI in health, and the complex ethical, legal and societal considerations involved, the three granting councils wish to support multidisciplinary research efforts in this domain. Of the $21.15 million available for this funding opportunity, up to $2.25 million is available to fund applications relevant to the Special Call: Artificial Intelligence, Health and Society. Program Launch: April 2018. Full details will be available on ResearchNet soon. Deadline for LOIs: May 2018; Full applications deadline: October 2018.
  • NEW: Partner Linkage Tool for CIHR Early Career Investigators in Maternal, Reproductive, Child and Youth Health (2018) funding opportunityThe aim of the Partner Linkage Tool is to facilitate new collaborations between Applicant Funding Partners and Early Career Investigators. As such, we invite partners with funding available to share information about their priorities and details of any process/selection criteria associated with accessing this funding. We also invite Early Career Investigators to share their information and research focus for the attention of interested partners. Reminder: Registration closes April 17, 2018 but applicant partners can still be added up to the Application deadline of May 15, 2018.
  • Brain Tumor Funders' Collaborative (BTFC). The BTFC is requesting proposals on the role of the neuro-immune system in the origin and progression of the immune responses in primary human brain tumors with the hope of developing immunotherapies for treatment of these tumors in patients. The initial response to the RFP requires pre-proposals describing studies on the complex roles of immune responses in the context of primary brain tumors in pediatric and/or adult human patients. Maximum amount: $250,000 per year for three years. Deadline for pre-proposals: May 11, 2018.
  • Cystic Fibrosis Foundation: Research Grants. Research grants are intended to support basic science research. Studies may be carried out at the subcellular, cellular, animal, or patient levels. Priority will be placed on those projects that propose to better understand the mechanisms behind disease pathophysiology and to develop strategies to prevent or treat CF. Support is available for $125,000 USD per year (plus 8 percent for indirect costs) for up to two years, at which time a grant may be competitively renewed for additional funding. Deadline for applications: May 7, 2018.
  • Bill & Melinda Gates Foundation: Global Grand Challenges - Explorations (Round 21). Maximum amount: $100,000 USD for initial grants. Successful projects are eligible to receive and additional $1,000,000 USD. Deadline for submissions: May 2, 2018.
  • The Michael J. Fox Foundation (MJFF): Targeted Funding Opportunities. MJFF will be hosting a funding opportunities INFORMATION WEBINAR on May 10, 2018 from 12pm - 1pm US ET.
    The deadline for pre-proposals is May 31, 2018.
  • Dementia Consortium. The Dementia Consortium aims to expedite the development of new drugs for dementia by supporting research into novel targets for neurodegeneration. It brings together the voluntary, academic and private sectors in order to tackle the growing dementia problem. The Consortium seeks to end the ten-year wait for a new dementia treatment by closing the gap between fundamental academic research and the pharmaceutical industry’s drug discovery programmes. It provides funding, expertise and resources to support new drug targets emerging from academic research that hold the promise of patient benefit. The Consortium is looking for novel targets in the areas of neurodegeneration and dementia generated by scientists at academic institutions in the UK and the rest of the world. We support target validation studies: preclinical research that aims to give confidence in the relevance of a novel target to a disease. Visit here for details on how to apply. The next deadline is April 23, 2018.

March 14, 2018

  • Centre for Addiction and Mental Health (CAMH):  Discovery Fund Seed Funding. The objective of the Seed Funding Competition is to provide support for innovative, new solutions to solving major challenges in the diagnosis, treatment and prevention of mental illness, and to support investigators during the critical period between the initiation of research and the receipt of sustained funding. The Discovery Fund seed funding competition is interested in funding projects focused on applying concepts of clinical research to better identify, diagnose and treat mental illnesses. Projects will be assessed and awarded under the listed research themes. These research themes have equal weight of importance and no theme is more superior or favored over another. Deadline for applications: April 3, 2018 at 12pm.
  • Ontario Centres of Excellence: Health Technologies Fund - Round 3. The Health Technologies Fund (HTF) supports the development of made-in-Ontario health technologies by accelerating evaluation, procurement, adoption and diffusion in the Ontario health system. HTF is a program of the Government of Ontario, developed by the Office of the Chief Health Innovation Strategist (OCHIS), administered by the Ontario Centres of Excellence.  The fund is part of the OCHIS’ mandate is to strengthen Ontario’s health innovation ecosystem. The deadline for applications is May 7, 2018. The Health Technologies Fund Round 3 Application Development Workshop will be held on March 21 between 2:00 pm and 4:00 pm and is now open for registration. This final round calls for solutions addressing: 
    • Client and Care Team Communication – Solutions that change how clients and caregivers communicate with their care team
    • Continuity of Care Providers – Solutions that improve logistics and routing to allow home and community care providers to better match staff skills, competencies and availability with client needs
    • Supporting Clients to Live Independently – Solutions that enable older adults and home care clients to age in place and live independently
  • Diabetes Canada:
    • New Investigator Award: to provide operating support and salary (if required) to independent researchers at the beginning of their careers. The research must describe related projects which are all aligned to achieve objectives that have impact on people living with and impacted by diabetes. Deadline for applications: April 2, 2018 at 8pm.
    • Diabetes Investigator Award: to provide operating support to independent researchers through the bulk of their careers. The research must describe related projects which are all aligned to achieve objectives that have impact on people living with and impacted by diabetes. Deadline for applications: April 2, 2018 at 8pm.
  • ALS Canada: Project Grant Program. This program combines Discovery Grant, Bridge Grant and Clinical Management Grant streams. ALS Canada anticipates funding 8 x $125,000 grants for use over 1 or 2 years. The program provides funding for high risk/high reward with little preliminary data, continuation of ongoing high quality research, studies to improve the quality of life for people with ALS. Deadline for applications: June 8, 2018 at 1pm ET.
  • Workers Compensation Board (WCB) of Manitoba: Research and Workplace Innovation Program 2018. The WCB has created the Research and Workplace Innovation Program (RWIP) to promote and fund scientific research, workplace innovation, training and education projects and knowledge transfer related to prevention of occupational injuries, diseases and return to work of injured or ill workers. RWIP Projects are funded under three (3) streams: Scientific Research, Training and Education and Workplace Innovation. Generally, each project would be up to two years in duration and funded up to a maximum of $100,000 each year. A total of $1 million is available to fund qualified projects. Deadline for Notices of Intent: March 27, 2018 (for Scientific Research) with an application deadline of May 22, 2018. Application deadline for other streams: June 26, 2018.
  • Crohn's & Colitis Foundation:
    • Litwin IBD Pioneers Initiative supports innovative clinical and translational research projects with the potential to impact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, identification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds innovative pilot research so that scientists can test their initial ideas and generate preliminary data. The program is also open to investigators from other disciplines new to the IBD field. Upper amount: $130,000 USD for up to two years. Deadline for Letters of Intent: April 30, 2018.
    • Senior Research Awards provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources such as the National Institutes of Health (NIH). Upper amount: $115,000 USD (including indirect costs) per year for up to 3 years. Deadline for Letters of Intent: May 1, 2018.
  • Lupus Research Alliance: Distinguished Innovator Awards in Lupus. The Distinguished Innovator Awards provide outstanding scientists with substantial support for up to four years to conduct novel research into the fundamental causes of systemic lupus erythematosus and so provide new directions towards a cure . The Lupus Research Alliance welcome s novel, hypothesis - or discovery - driven proposals in human and/or animal - model based lupus research. The research proposal must aim to uncover the fundamental causes of lupus and present a compelling vision of how the discovery would lay the groundwork for a cure, prevention, or highly effective therapy. Applications will be judged primarily on the novelty and potential of the research proposal, and the strengths and track record of the investigator. Grants will be supported for up to $250,000 USD per year for up to four years. Deadline for 2 page Letters of Intent has been extended to March 20, 2018
  • Pfizer Inc.: ASPIRE Gene Therapy for Hemophilia Research Awards Program. Ongoing basic science research and clinical research are critical to deepen understanding of disease mechanisms and to ensure advancement of management strategies for hemophilia and related comorbidities. In an era of increased competition for research funding, the 2018 ASPIRE Gene and anti-TFPI Therapies in Hemophilia Global Research Awards Program is designed to support laboratory and clinical research in pathogenesis, complications, management, and clinical outcomes of these therapies for hemophilia. Upper amount: $125,000 USD per year for up to two years. Deadline for applications: May 31, 2018.
  • Pfizer Inc.: Addressing the knowledge gaps in the identification and optimal management of CV risk. Cardiovascular diseases continue to be a major cause of morbidity and mortality across the globe. Low income and middle income countries bear a significant part of this burden. Increasing awareness of CV risk factors and diseases, continuing HCP medical education of early identification and the optimal management of CV risk will be important in reducing the impact of this burden in communities worldwide. Their intent is to support medical educational projects that will help strengthen the knowledge and competence of Primary Care Doctors/ Cardiologists and other HCPs in diagnosing and managing CV risk and particularly dyslipidemia and hypertension. Individual projects requesting up to $250,000 USD will be considered. Larger grants may be considered depending on scope and merit of proposal. Deadline for applications: April 16, 2018.
  • Friedreich's Ataxia Research Alliance (FARA): Kyle Bryant Translational Research Award. FARA accepts LOIs focusing on pre-clinical and clinical investigations that will advance treatments for FA. The specific aims must target one or more of the following: 1) Identification of biomarkers for FA that will elucidate disease variability, severity, and prognosis; facilitate drug screening, and/or optimize selection of patients and clinical endpoints for clinical trials; 2) Development of tools and technologies that can (a) be directly used for therapy development; (b) overcome existing obstacles to treatment and (c) be directly applied to, or adapted for, delivery of potential therapeutics; 3) Pre-clinical development and testing of potential therapeutics, biologics, and devices in cells and animals; 4) Clinical studies of patient outcome measures, potential interventions, or devices. The applicant may request a budget of up to $250,000 USD per year for one or two years. Deadline for Letters of Intent: May 15, 2018.


March 8, 2018

  • CIHR - Clarifying the Fall 2017 Project Grant funding resultsIn follow-up to the Fall 2017 Project Grant results, CIHR would like to clarify the mechanisms by which funding decisions are made within the Project Grant program. They recognize that the Notice of Decision documentation does not adequately explain the complexities of funding decisions, and we are working to redesign this material for future competitions. Further details here.

    Please note that CIHR has also made data, which are broken down by panel, from this competition available on a separate web page. It is critical that these data not be used to inform an applicant’s panel selection for future competitions, as they are based on many factors (further explained below) and will change from one competition to the next. The most important factor for an applicant to consider when selecting a panel is the expertise required to review the application. CIHR encourages members of the community with questions and/or suggestions for further information to get in touch with the Contact Centre at support@cihr-irsc.gc.ca.
  • CIHR Institute Advisory Board (IAB) member applications now open.  CIHR has officially launched the 2018 Institute Advisory Boards (IAB) membership renewal. Open and transparent, this recruitment process will focus on filling remaining gaps in expertise on IABs, which are made up of individuals from Canada and abroad – reflecting the greatest possible diversity and the highest standards of excellence across the following dimensions: research expertise, community sectors, additional experience/expertise; and demographics. The total number of members on an IAB is between 8-14, and selection criteria and composition of the IABs is available on the CIHR websiteApplications are being accepted on ResearchNet until April 9, 2018. For full details on how to apply please Institute Advisory Board Member application and guidelines.
  • Ministry of Research, Innovation and Science (MRIS): Early Researcher Award (ERA) Round 14. The ERA program helps promising, recently-appointed Ontario researchers build their research teams of undergraduates, graduate students, post-doctoral fellows, research assistants, associates, and technicians. The ERA program will provide funding up to $100,000 for each award (plus $40,000 for indirect costs), and must be matched by an additional $50,000 (cash not in-kind) from the division/department and/or a partner organization. The funds are to be used over a period of five years to fund eligible expenses (e.g. salaries and benefits, essential and reasonable travel and expenses related to conferences for trainees, workshops, seminars, and/or offsite research activities) for building a research team. Eligible applicants are those who have started their academic career on or after July 1, 2013, and have completed their first Doctor of Philosophy, Doctor of Veterinary Medicine degree, Medical Doctor or terminal degree on or after July 1, 2008. The program will take into consideration eligible disruptions (such as required training and parental leave). Please see the program guidelines for further details. Deadline for a mandatory, non-binding Notice of Intent (NoI) is May 25, 2018 at the Research Services Office. Further details about the submission process can be found here. Information sessions will be held, further details to follow.
  • Cancer Research Society: UpCycle. The Cancer Research Society has launched UpCycle, their new drug repurposing funding program, which aims at paving a new way toward innovative therapeutic options in the field of cancer. Canadian researchers who submit the most promising drug repurposing projects will have the opportunity to obtain funding in an amount up to $100,000 to explore and develop their hypotheses. Projects should aim to evaluate off-patent drugs used for other indications than cancer, and demonstrate their potential efficacy in preventing or treating cancer. This initial funding will be granted beginning in the fall of 2018. The Society also plans to provide additional support over the next few years to help advance the most impactful projects. Questions should be directed to Lucille Beaudet or Irina Navarrette at grants@src-crs.ca or call 416 861-9227, toll free 1 888-766-2262. Deadline for Letters of Intent: March 27, 2018.
  • Molly Towell Prenatal Research Foundation: New Investigator Awards and Fellowships. The Foundation will support original and innovative research, which she defined as the pursuit of new information derived from basic biomedical or clinical research. High priority is given to projects that concern fetal growth or metabolism but any studies that involve original research in fetal or neonatal medicine will be considered. However, purely epidemiological research or clinical trials will not be considered. New Investigator Awards and Fellowships are available. Deadline for applications: April 20, 2018.
  • Brain Tumour Foundation of Canada Grant Program. Proposals that receive funding include research that involves any and/or all of the following: The development of new concepts; Patient-oriented research such as clinical trials, epidemiological studies, quality of life studies, outcomes, health services research; Pre-clinical research evaluating the therapeutic potential of recent discoveries in the basic mechanisms of either brain tumour pathogenesis or experimental therapeutics. Innovative research proposals such as those that incorporate novel or original concepts that have the potential to make a difference are also considered. Applications for grants up to $25,000.00 will be considered. Deadline for applications: April 27, 2018.
  • Scottish Rite Charitable Foundation (SRCF): Major Research Grants. SRCFC Major Grants support biomedical research into intellectual impairment focused on the following: 1) The causes and eventual cure of intellectual impairment, such as Dsylexia and Autism, especially as it affects children. 2) The causes and eventual cure of Alzheimer’s Disease and other neurodegenerative diseases. 3) Research into other forms of intellectual impairment may be considered. The value of the grants is a maximum of $40,000 per year for a period of up to 3 years. Deadline for applications: April 30, 2018.
  • Huntington's Disease Society of America: HD Human Biology Project. The goal of the program is to offer support for investigator-initiated research directed to better understand the biology of Huntington's disease (HD) as it occurs in humans. The research projects and observations resulting from them should have the potential to directly impact the lives of patients or help guide future drug development for HD. HDSA is interested in sponsoring innovative lines of inquiry of human HD patient data that will shed light on the most proximal biological events caused by the mutant huntingtin gene. All research proposals must incorporate a patient-centric focus to understanding HD. Deadline for Letters of Intent: May 22, 2018.
  • Tuberous Sclerosis Alliance (TS Alliance): Research Grants Program. Most TS Alliance research grants support small, focused projects that allow investigators to develop preliminary data to compete for funding from larger organizations such as the National Institutes of Health (NIH). Other TS Alliance research grants support post-doctoral fellowships to encourage young investigators to engage in TSC research. The TS Alliance offers Postdoctoral Fellowships and Research Grants. Maximum total costs of $75,000 USD per year for up to two years. Deadline for Letters of Intent: May 7, 2018. 
  • National Center for Responsible Gaming (NCRG). 
    • Large Grants for research on gambling disorders: The Large Grants program provides support for discrete, specified, circumscribed research projects related to gambling disorders. Upper amount $150,000 USD for up to 24 months. Deadline for Letters of Intent: June 1, 2018.
    • Seed Grants for research on gambling disorders: The NCRG is open to supporting a variety of projects exploring the etiology, prevention and treatment of gambling disorder. Upper amount $30,000 USD for up to 12 months. Deadline for applications: August 1, 2018.
  • NIH: Various Opportunities. Unless otherwise stated in the funding opportunity, see Standard Due Dates Schedule for deadlines for each Grant category. If you intend to apply via the University of Toronto, it is recommended you contact Krista Montgomery in Research Services at least two weeks prior to submitting an NOI or application.  For more information on NIH application and the submission process, please visit the University's Research Funding Opportunities found here.
    • Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33)
    • Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01)
    • Clinical, Behavioral and Physiological Research Testing Current and Novel Closed Loop Systems (R01- Clinical Trial Required)
    • Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (R01 Clinical Trial Required)
    • Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R01)
    • The Characterization and Discovery of Novel Autoantigens and Epitopes in Type 1 Diabetes (R01)
    • Funding For Collaborative Clinical Research In Type 1 Diabetes: Living Biobank (R01)
    • Elucidating the Effect of Glycemic Excursions on Patient Well-being and Cognitive Status in People with Type 1 Diabetes (T1D) (R01)
    • Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01)
    • Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults (R01) and (R21) and (R34)
    • Genetics of Alcohol Sensitivity and Tolerance (R01)
    • Mechanisms of Alcohol Tolerance (R21/R33)
    • Basic Research in Cancer Health Disparities (R01) and (R21)
    • BRAIN Initiative: New Concepts and Early - Stage Research for Large - Scale Recording and Modulation in the Nervous System (R21)
    • Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R03) and (R01)
    • Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01)
    • Innovative Therapies and Tools for Screenable Disorders (R01) and (R03) and (R21)

February 28, 2018

  • Weston Brain Institute: 2018 Funding Opportunities. 
    • Rapid Response: Canada 2018 (Alzheimer's and Related Diseases). Seed funding for novel, high-risk, high-reward translational research ideas to accelerate the development of safe and effective treatments for neurodegenerative diseases of aging.  Applications in this round must relate to the following disease(s):  AD, FTD, MCI, vascular contributions to these diseases, and prodromes to these diseases. Award amount: Up to $200,000 over up to 18 months. Program information session: March 8, 2018 at 1pm ET. Register here. Deadline for Letters of Intent: April 19, 2018 at 2pm ET.
    • International Fellowships: Canada 2018. The goal of this new funding opportunity is to support top Canadian PhD students to travel to and work in world-renowned labs for up to 12 months during their PhD, and to further their translational research on neurodegenerative diseases of aging. Funding available is $60,000 per year, prorated at $5,000 per month to fit short travel and specific project needs. Program information webinar: March 22, 2018 at 1pm ET. Register here. Deadline for applications: April 30, 2018.
    • Early Phase Clinical Trials: Canada 2018. This program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data. Funding available is a maximum of $1.5 million over up to 4 years. Project must involve the development of a therapeutic, and/or a tool to help accelerate the development of therapeutics for neurodegenerative diseases of aging. Applications are accepted on a rolling basis and an LOI may be submitted at any time.
  • GSK Biology Discovery Partnerships with Academia (DPAc) for Alternative Drug Discovery and Development. The Innovations & Partnerships Office (IPO) along with our hospital partner TTO's have been in discussions with GSK over the last few months.  As a result of these discussions we are pleased to announce that a Toronto specific event has been launched by the GSK Discovery Partnerships With Academia (DPAc) team. What is the GSK DPAc Program?  A novel approach to early drug discovery that is designed to provide academic researchers access to industrial drug discovery resources and expertise;
    -          Brings together the insight and creativity of academia with the drug discovery expertise of GSK to establish truly integrated partnerships that can translate innovative research into medicines that benefit patients;
    -          Each selected project operates as a joint team, with both parties working toward shared goals and with open sharing of information and data;
    -          DPAc provides funding to cover project costs within the academic lab & contributes resources and in kind efforts to accomplish the GSK-specific portions of the collaboration.
    Benefits to yourself, process details & associated time-lines for proposal submissions can be found here. The deadline for proposals is March 12, 2018.
    Further information for applicants
    GSK DPCa: Non-confidential Project Insight Form
    GSK DPCa: Confidential Project Insight Form

  • Launch: CIHR Early Career Investigators in Maternal, Reproductive, Child and Youth Health (2018). The program will fund research across the four CIHR research themes (biomedical, clinical, health systems services, and population health) that has the potential to have a significant impact on maternal, reproductive, child and youth health outcomes according to the mandates of the participating CIHR institutes. Ultimately, the program aims to strengthen Canada's capacity and knowledge to respond to challenges and needs by providing important early career development support to researchers in these fields. The maximum amount per grant from CIHR is $35,000 per year for up to 3 years for a total of $105,000. The CIHR contribution must be matched at a minimum of 1:1 by the successful applicant’s host institution and/or other partner(s). Matching funds must be 100% cash contributions. Registration deadline: April 17, 2018; Application deadline: May 15, 2018.
  • The Canadian Cancer Society:
    • Impact Grants. It is anticipated that approximately 7 grants will be awarded in this competition, with approximately 3 of these being breast cancer grants. Deadline for LOIs: April 10, 2018.
    • Awards for Excellence in Cancer Research. The nomination deadline is Wednesday, April 18, 2018
    • Chordoma Research Grant Competition (Coming soon). It is anticipated that up to 2 grants will be awarded in this competition. Grant budgets may be up to $100,000 per year and a maximum of $150,000 per grant. Grants will be non-renewable. To receive notification when the competition is open for applications, please contact research@cancer.ca
    • Junior Investigator Grant Panel Travel AwardThe Canadian Cancer Society is pleased to offer a special initiative to allow junior investigators in cancer research to gain knowledge and understanding of the Canadian Cancer Society peer-review process. Selected investigators from across Canada will be provided funds to reimburse travel costs to Toronto to observe a grant panel meeting. This unique opportunity will provide junior faculty members with an “inside look” at how research grants are reviewed in order to help structure their own grant proposals in future.
  • DEBRA International: Epidermolysis Bullosa (EB) Research. The current research priorities are: 
    - Improve the understanding of the biology and genetics of all forms of Epidermolysis bullosa (EB), as better understanding can lead to new approaches to diagnose and treat EB 
    - Work towards the development of therapies (including possible gene-therapies, cell-therapies, drug therapies or protein therapies) 
    - Understand the nature of wound healing and the development of skin cancer in EB, and seek to develop better treatments and prevention strategies 
    - Support clinical care research to improve the management of EB through symptom relief. 
    Deadline for applications: March 26, 2018.
  • Dutch Duchenne Parent Project NL (DPP NL): Research GrantsDPP NL stimulates research in the search for a cure for Duchenne Muscular Dystrophy. DPP NL sponsors promising research and fellowships, faster exchange of data and international collaboration. Both research projects and fellowships may be submitted. Researchers from all countries may submit research projects at DPP NL. The amount of funding is unspecified and will be for a maximum of two years. Deadline for applications: April 15, 2018.
  • VHL Alliance: VHLA Research Grant Program. The VHL Alliance is pleased to announce a call for applications for research grant support on topics relevant to von Hippel-Lindau disease. Projects should further the understanding of VHL disease and may address VHL cell and molecular biology, the development and/or application of VHL-relevant animal models, or the diagnosis and treatment of VHL patients. There will be two potential funding mechanisms:- Research Projects (up to $100,000 USD over two years) - Pilot grants (up to $25,000 USD over one year). Deadline for Letters of Intent: June 1, 2018 (anticipated).
  • Sanfilippo Children's Foundation. The mission of the Sanfilippo Children's Foundation is to drive research, enable access to effective treatments and improve the quality of life for Australian children affected by the fatal childhood disease, Sanfilippo Syndrome. Translational Research Grants fund projects up to $500,000 AUD/year for up to 3 years. Incubator Grants fund projects up to $90,000 AUD for 1 year if a salary is included in the costing. If a salary for the researcher has already been secured from another funding body, applications within the region of $25,000 AUD would be considered. Deadline for Expressions of Interest: April 3, 2018.
  • A Foundation Building Strength (AFBS): Building Muscle Initiative Research Grant. AFBS is a non-profit organization striving to stimulate and advance the science of treating Nemaline Myopathy, ultimately laying the groundwork for the development of commercially available treatments for these diseases. AFBS is excited to announce a new initiative to fund up to $1 million in research grants. Application deadline: TBA.
  • Microsoft Genomics for Research (New). The Microsoft Genomics for Research program awards Microsoft Azure cloud computing resources to researchers interested in testing and developing their own next-generation sequencing (NGS) pipelines using the Microsoft Genomics service. Microsoft Genomics is an easy-to-use, scalable cloud service for secondary analysis of genomes. The service is an optimized version of the Broad Institute's best practices pipeline, BWA-GATK. These awards are intended to drive exploration and discovery by providing an easy-to-use service for secondary analysis of genomes. Application deadline: April 15, 2018.

February 15, 2018

  • CIHR Institute Advisory Board (IAB) member applications now open. CIHR has officially launched the 2018 Institute Advisory Boards (IAB) membership renewal. Open and transparent, this recruitment process will focus on filling remaining gaps in expertise on IABs, which are made up of individuals from Canada and abroad – reflecting the greatest possible diversity and the highest standards of excellence across the following dimensions: research expertise, community sectors, additional experience/expertise; and demographics. The total number of members on an IAB is between 8-14, and selection criteria and composition of the IABs is available on the CIHR website.  Applications are being accepted on ResearchNet until April 9, 2018. For full details on how to apply please Institute Advisory Board Member application and guidelines.
  • CIHR Gender-Net Plus: Call for ProposalsCIHR has announced that funds are available to support Canadian researchers interested in investigating sex and gender in health through transnational collaborations. Through the leadership of the CIHR Personalized Health Initiative, the CIHR Institute of Gender and Health is a member of GENDER-NET Plus - an international consortium of 16 research funders in 13 countries. These 16 partners have joined forces to launch a co-funded Call for Proposals, to support research that aims to address urgent societal challenges through a sex and gender lens. The recorded applicant webinar, linkage tool, partners list and timelines for this funding opportunity can now be accessed on the CIHR Gender-Net Plus website.
    Pre-proposal deadline to Gender-Net is March 1, 2018, 5 p.m. CET, and the full application deadline to CIHR is July 16, 2018.
  • Team Grants in Nutrition and the Epigenome. The aim of this call is to support transnational, collaborative research projects that gain a better understanding of the diet-epigenome relationships and their effect on human health. This will allow the development and scientific substantiation of intervention strategies for treating nutrition-related diseases and sustaining good health throughout the life course. The total CIHR amount available for the Canadian component of successful projects is $900,000 CAD, enough to fund approximately two grants. The maximum amount per Canadian component of the grant is $150,000/year for up to three years. More details are available at Joint Programme Initiative Healthy Diet for a Healthy Life (JPI HDHL).  The application deadline is April 12, 2018.
  • ERA-NET NEURON: 2018 Mental Disorders. The aim of this call is to facilitate multinational, collaborative research projects that will address important questions related to mental health and mental disorders across the entire lifespan. In addition to the application submission (in English) to the NEURON Joint Call Secretariat, Canadian consortium members applying for CIHR funding must complete an abbreviated CIHR application (in either of Canada's official languages) and submit it using ResearchNet. Deadline for pre-proposal submissions: March 8, 2018.
  • Azrieli Foundation and Brain Canada launch: Early-Career Capacity Building Grants. This program is targeting Early-Career Researchers, within 3 years of their first research or university appointment, and will provide $100,000 over 2 years that will enable innovative and original research with the high potential for a meaningful impact. The general purpose of the Early-Career Capacity Building Grant program is to accelerate novel and transformative research that will fundamentally change our understanding of nervous system function and dysfunction and their impact on health. The goal is to reduce the social and economic burden of neurological and mental health problems by prevention, early diagnosis, and treatment. Deadline for full applications: April 17, 2018 at 4pm ET.
  • NIH Common Fund for Somatic Cell Genome Editing. This funding opportunity aims to support the establishment of a dissemination and coordination centre for the NIH somatic cell genome editing consortium.  The consortium will create validated techniques on genome editing tools, delivery systems, animal models and biological assays. Awardees participating in the consortium will develop consensus policies and procedures for activities such as data sharing. Read moreApplications will be open on March 3, 2018 with an end date of April 3, 2018.
  • LGS (Lennox-Gastaut Syndrome) Foundation. The LGS Foundation's seed grant program awards research grants to young investigators, physician residents, and clinicians who are interested in studying Lennox-Gastaut Syndrome (LGS), a rare and often debilitating form of childhood-onset epilepsy. These seed grants are intended to help researchers explore novel ideas and answer questions related to the clinical aspects, therapies and/or genetic causes of LGS. Seed Grants and Post-Doctoral Fellowships are available. The seed grant program awards one-year research grants up to $30,000 USD and two-year grants up to $50,000 USD. Deadline for letters of intent: March 1, 2018.
  • Pfizer Inc.: Understanding the Importance of Calcium and Vitamin D Supplementation for Aging Men. The intent to support projects that focus on increasing the awareness about elements essential to healthy ageing in men and the components that need to be managed to maintain. Primary focus should be on bone health and Calcium and Vitamin D supplementation. The target learner audiences include healthcare professionals with a focus on prevention and treatment of male osteoporosis, and General practitioners. The total available budget is $200,000 USD. Deadline for applications: March 19, 2018.
  • Organization for Autism Research (OAR): Applied Research Competition. OAR seeks to fund studies that expand the body of knowledge related to autism intervention and treatment, produce practical and clearly objective results, have the potential to impact public policy, and provide outcomes that offer to enhance quality of life for persons with autism and their families. While applicants are always free to submit on any relevant area of research or intervention, this year, OAR is placing an emphasis on research that addresses the following targeted areas: healthcare transition, generalization of technology-based intervention, community-based intervention, residential services and supports, literacy, and sexuality education. OAR will consider awarding up to 8 grant awards for $30,000 USD. Deadline for preliminary proposals: March 26, 2018.
  • International Essential Tremor Foundation (IETF): Grant Program. The aim of this request is to stimulate inquiry into this poorly understood clinical disorder and to provide support to projects that are innovative and give promise of receiving more substantial support from NIH, K Award or R01 and/or other sources if sufficient preliminary information can be obtained from projects supported by the IETF. Upper amount $25,000 USD. Deadline for proposals: February 28, 2018.
  • National Organization for Rare Diseases: Current Research Funding Opportunities. Deadlines are ongoing. Questions should be directed to research@rarediseases.org
    • Cat Eye Syndrome – One grant of up to $30,000 for scientific and/or clinical research studies related to Cat Eye Syndrome
    • Malonic Aciduria – One grant of up to $50,000 for scientific and/or clinical research studies related to Malonic Aciduria
    • Post-Orgasmic Illness Syndrome – One grant of up to $31,000 for scientific and/or clinical research studies related to Post-Orgasmic Illness Syndrome (POIS)

February 7, 2018

  • The College of Reviewers (College) is pleased to announce the launch of its Membership Progression Program. The College is developing capacity through its Membership Progression Program to allow those individuals who do not currently meet all of the academic membership selection criteria to become a part of the College. The program provides an opportunity for new or less experienced reviewers to build the reviewing skills and experiences necessary to be eligible to obtain full College Member status. Those invited to join the College as an Associate Member are provided with the training and support to develop their reviewing skills, as well as the direct hands-on peer review experience to reinforce how to conduct quality reviews. Recruitment begins in February 2018! Read more.
  • Gordon F. Cheesbrough Research Chair in Family and Community Medicine, North York General Hospital and Director, UTOPIAN, University of Toronto Department of Family and Community Medicine. North York General Hospital (NYGH) and the University of Toronto invite applications for the joint position of Gordon F. Cheesbrough Research Chair in Family and Community Medicine and Director, UTOPIAN – the University of Toronto Practice-Based Research Network. The Gordon F. Cheesbrough Research Chair in Family and Community Medicine was established at NYGH to support an outstanding academic individual with a demonstrated track record in research excellence. This individual will also be the Director of UTOPIAN, which is a practice-based research network of 14 academic family medicine teaching units affiliated with the University of Toronto Department of Family and Community Medicine (DFCM). Review of applications will continue until March 31, 2018. Read the full posting.
  • Prostate Cancer Foundation: 2018 PCF Challenge Awards for Metastatic, Lethal Prostate Cancer (A Request for Team Science Applications). These awards will be funded depending on the level of innovation in applications received. High risk, currently unfunded projects are most desired. They especially seek applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer. The Movember Foundation will fund approximately three (3) Movember Foundation-PCF Challenge Awards from U.S.-based teams with money it has raised in the U.S. Other funding sources will support additional PCF Challenge Awards at institutions from within or outside the U.S. View the RFA for complete details. Deadline for applications: April 23, 2018 at 3:00pm EDT.
  • Cancer Research Society: LAUNCH - Scholarships for the Next Generation of Scientists: 2018 Competition. This initiative is aimed at supporting future generations of Canadian researchers. Questions should be directed to Lucille Beaudet or Irina Navarrete at grants@src-crs.ca or, toll free, 1 888-766-2262. Deadline for applications: April 27, 2018 EST. Visit their website for additional information.  The Scholarship is broken down into two parts, and extends over a period of 3 years, with no possibility for renewal.
    • Part 1: Postdoctoral Salary Award - 1 year - $40,000
    • Part 2: Operating Grant - 2years - $120,000 ($60,000 per year)
  • Networks of Centres of Excellence (NCE): AGE-WELL SIP Accelerator Program. AGE-WELL is dedicated to the creation of technologies and services that benefit older adults and caregivers. Their aim is to help older Canadians maintain their independence, health and quality of life through technologies and services that increase their safety and security, support their independent living, and enhance their social participation. AGE-WELL’s SIP Accelerator program supports innovative post-discovery projects focused on the commercialization and/or knowledge mobilization of solutions (e.g. technologies, services or policies) aligned with AGE-WELL’s mission and vision . The program provides financial support (up to $40,000 over 1 year, may be renewed for an additional year); training opportunities; and strategic mentorship. UofT internal deadline: February 24, 2018; Sponsor deadline: March 2, 2018.
  • ERA PerMed: Research Projects on Personalized Medicine – Smart Combination of Pre-clinical and Clinical Research with Data and ICT Solutions. ERA PerMed is an ERA-Net Cofund, supported by 31 partners of 22 countries and cofunded by the European Commission. The aim of this Funding Opportunity is to fund projects showing clinical feasibility of Personalized Medicine in complex/multifactorial diseases as well as other diseases (as monogenic, rare diseases and cancer). Applicants are expected to combine pre-clinical and/or clinical research with bio-informatics components to enable data quality on one side and the potential applicability for health care providers on the other side. Proposals must be interdisciplinary and clearly demonstrate the potential impact in PM as well as the added value of transnational collaboration: sharing of resources (registries, diagnosis, biobanks, models, databases, diagnostic and bio-informatics tools, etc.), platforms/infrastructures, interoperability of data harmonization strategies and sharing of specific know-how. Read more.
    Information Webinar: February 12, 2018, 1pm-2pm ET. Register here.
    Deadline for pre-proposals: April 10, 2018.
  • Canada-EU Commission Flagship Collaboration for Human data storage, integration and sharing. CIHR and FRQS are pleased to announce that funding is available to support Canadian researchers interested in collaborating in the domain of repositories storing and sharing human-omics data that will create a framework for long-term cooperation through transnational collaborations with European researchers. The goal of this program aims to enhance and standardize data deposition, curation and exchange procedures thus ensuring better data reuse and increased benefit to the scientific communities worldwide. This is a unique collaboration, and CIHR’s first European Commission Research and Innovation Action (RIA), which will require each project to involve at least one Canadian investigator and three European investigators fundable by the European Commission. The call for proposals was launched on October 27, 2017.  Read more
    Information Webinar: February 12, 2018, 11am-12pm ET. Register here.
  • Alzheimer's Drug Discovery Foundation (ADDF): Preclinical Drug Discovery. The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, other dementias and cognitive aging. Amount: $150,000-$600,000 USD based on stage and scope of research. Deadline for Letters of Intent: April 13, 2018.
  • National Marfan Foundation: Faculty Grant Program. The faculty grant program supports two-year grants for basic or clinical research for all disciplines in Marfan syndrome, Ehlers Danlos syndrome, Loeys Dietz syndrome and other related disorders. Work can be performed in the U.S. or internationally. Awards are $50,000 USD per year for two years. Deadline for proposals: April 20, 2018.
  • AACR-Johnson & Johnson Lung Cancer Innovation Science Grants. Proposals should focus on understanding the behaviors that lead to chronic exposures to respiratory carcinogens and how these behaviors can be modified; how chronic exposures produce cellular/genomic damage and how these can be ameliorated; deciphering the types of inflammation that underlie the carcinogenic process; understanding the alterations in innate and adaptive immunity that create an immune-permissive microenvironment; and changes in the pulmonary microbiome that may contribute to carcinogenesis. Proposals that characterize premalignant lesions or that substantially improve the detection of lung cancer at more curable stages will also be prioritized. This project must be implemented by a multi-institutional team, composed of Principal Investigators from at least two, but no more than three, different institutions. The Grant will provide $1.5 million USD in funding for direct and indirect expenses related to each research project over a three year timeframe. Deadline for applications: March 2, 2018.
  • International OCD Foundation (IOCDF): Young Investigator/Fellow Award and Breakthrough Award. The IOCDF awards grants to investigators whose research focuses on the nature, causes, and treatment of OCD and related disorders. Post-doctoral fellows are encouraged to apply; however, a letter from their mentor is required at the time of application. Senior investigators may also ask for grant funding for projects that would provide pilot data for future larger scale federal grant applications. Up to $50,000 USD per award for Young Investigator/Fellow Award and 2 awards of $500,000 USD over 3 years for the Breakthrough Award. Deadline for Proposals: February 28, 2018.

January 25, 2018

  • NEW - Ontario Ministry of Health and Long-Term Care (MOHLTC): Targeted Call for Patient-Oriented Research in Mental Health and Addictions.  The MOHLTC is excited to launch a new funding competition through the Ministry’s Health System Research Fund (HSRF). The Targeted Call for Patient-Oriented Research in Mental Health and Addictions will support 24-month grants of up to $250,000 per year for research with the potential to improve Ontario’s mental health and addictions system. Grants funded through this competition should demonstrate strong partnership with people with lived experience throughout the entirety of research project: from project conception and writing of the grant application through governance, implementation, data analysis and interpretation, and knowledge translation and exchange. Grant applications will be reviewed not only by scientific peer-reviewers, but also by people with lived experience and sector experts. Contact E-mail : ResearchUnit@ontario.ca. Deadline for mandatory Notice of Intent: February 20, 2018: Full application due: March 14, 2018.
  • Genome Canada:  Genomic Applications Partnership Program (GAPP) - 2 new rounds are open. The GAPP funds public-private research collaborations focused on developing genomics-derived technologies that address opportunities and challenges identified by industry, government, not-for-profits or other “Receptors” of genomics knowledge and tools. Key Program Highlights: Project budgets: $300K-$6M (total); Co-funding: 1/3 Genome Canada (max), 1/3 Receptor (min), 1/3 other; Award duration: 1 to 3 years; Stage: Downstream R&D/validation/pilot.
    Please contact Shobha Ramsubir, Senior Manager, Business Development and Research, to initiate your application and to obtain the application form (applicants are encouraged to do this well ahead of the due dates).
    Details and timelines can be found here.
    Examples of previously funded GAPP projects

  • LAUNCH: SickKids-CIHR-IHDCYH New Investigator Grants in Child and Youth Health. New Investigator Grants provide important early career development support to child health researchers. The competition is open to early career investigators from any CIHR eligible institution, who may apply for up to 3 years' support for research in biomedical, clinical, health systems and services, population and public health sectors. The maximum amount for a single grant is $300,000 ($100,000 per year for up to 3 years). Deadline for applications: April 20, 2018. 
  • CIHR Pre-announcement: CIHR Early Career Investigators in Maternal, Reproductive, Child and Youth Health (2018). The program funds research that has the potential to have a significant impact on maternal, reproductive, child and youth health outcomes. Ultimately, the program aims to strengthen Canada’s capacity and knowledge to respond to challenges and needs by providing important early career development support to researchers in these fields. The total amount available from CIHR for the 2018 funding opportunity is $1,260,000, enough to fund up to 12 grants.  III will fund 1 grant for a project relevant to its mandate. Registration: April 2018; Application: May 2018.
  • JDRF Canadian Clinical Trials Network (JDRF CCTN) and Eli Lily Canada Inc.: Postdoctoral Fellowships in Clinical Translation in T1D Program. Two Fellowships will be offered at $60,000 each for a term of one-year.  Please see the RFA for background, eligibility criteria, and application details. Application deadline: March 27, 2018.
  • Kidney Foundation of Canada (KFOC) and Partners: Alport Syndrome Research Funding. The objective of this research funding program is to advance the knowledge of, develop effective treatment protocols for, and discover a cure for Alport Syndrome Foundation. Funding will be provided for basic science or clinical research on Alport Syndrome. These funds may be used as seed funding for the testing of initial hypotheses and the collection of preliminary data leading to successful long-term funding by the National Institutes of Health (NIH), the Canadian Institutes of Health Research (CIHR), or other major funding institutions around the world. It is anticipated that two research projects will be selected for funding, totaling $100,000 USD each, over a one- to two-year timeframe. Deadline for applications: February 9, 2018.
  • Canadian Liver Foundation: Operating Grants. Deadline for applications: March 31, 2018.
    • Two grants may be awarded to researchers in Canada whose research projects are related to hepatobiliary research
    • One grant may be awarded to a researcher in Ontario whose research project is related to liver cancer
    • One grant may be awarded to a researcher in Ontario whose research project is related to pediatric liver disease
  • Association for Frontotemporal Degeneration (AFTD): Pilot Grants - Nonpharmacological Therapies and Tools for FTD Pilot Grant (NEW). AFTD is pleased to announce a Request for Proposals for a new Pilot Grant focused on nonpharmacological interventions and tools with the potential to have a positive impact on the quality of life for persons diagnosed and their families. The grant is open to US and international investigators. New or early-career researchers within 10 years of their first faculty appointment or equivalent in a for-profit organization are especially encouraged to apply. Upper amount: up to $60,000 USD for one year. Deadline for applications: March 19, 2018.
  • CHEST Foundation Grants. Applicant Qualifications:
    - CHEST membership at time of application. 
    - Applicants must be licensed physicians. Physicians-in-training (residents or fellows), other health-care professionals, or clinical researchers with relevant experience will also be accepted. Although applicants may be at later career stages, special consideration will be given to young investigators and applicants in early stages of their careers. 
    - Teams are encouraged to apply but must have a representative to serve as the Principal Investigator who will apply as an individual and will receive recognition if awarded. 
    Please visit their website to see the full list of the 2018 Requests for Proposals for grant funding.  Deadline for applications: April 9, 2018.
  • Alliance for Cancer Gene Therapy (ACGT): 2018 Investigator Award in Cell and Gene Therapy for Cancer. ACGT funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. Preference will be given to those working in solid tumors, orphan tumors or pediatric tumors, and to research not previously funded, thus highly innovative proposals. Candidates  must hold an MD, PhD, or equivalent degree and must be tenure-track or tenured faculty. Award amount: Up to $500,000 over 2-3 years. View the RFA for further details and how to apply. Abstract Deadline: March 13, 2018 at 11 am EST; Deadline for invited complete applications: May 15, 2018 at 11 am EST.

January 17, 2017

  • Medicine by Design Postdoctoral Fellowship Award 2018. Medicine by Design   is accepting applications for its 2018 Postdoctoral Fellowship Award. This award will provide funding to high calibre postdoctoral candidates at University of Toronto and its affiliated hospitals with outstanding potential to become independent researchers in the regenerative medicine field. Each award is up to a maximum of $50,000/year for three years towards salary support, from April 1st, 2018 to March 31st, 2021. Funds cannot be used for travel or other expenditures. Please download the guidelines and application form for eligibility critieria and further details. Questions should be directed to awards.mbd@utoronto.ca. Deadline for submissions: February 5, 2018 at 5pm EST.
  • CIHR Observer Program - Opportunity for Early Career Investigators: Call for expressions of interest. CIHR is pleased to continue to offer an Observer program for early career investigators (ECIs) to participate as an observer in the peer review process of the Project Grant: Spring 2018 competition. Selected ECIs will be invited to observe committee meetings taking place in Ottawa as part of the review process for the Project Grant competition. There will be one ECI per committee.  As observers, the ECIs will not participate in review discussions. The face-to-face meetings will be held in Ottawa in May and June 2018. Exact dates will be confirmed with each selected ECI once they are assigned to a committee. CIHR will cover the travel costs for the ECI to attend the committee meeting. Deadline for expressions of interest: February 21, 2018.
  • Holland Bloorview Kids Rehabilitation Hospital: 2018 Pursuit Award Competition. The 2018 Pursuit Award competition, recognizing outstanding achievements in childhood disability research by PhD students and recent alumni from across the globe. Eligibility: Current PhD students (less than six months away from defence), postdoctoral trainees, and recent graduates (within one year of receiving their PhD) with a focus in any applied or clinical research specifically linked to childhood disability. Criteria: Finalists are chosen based on significance of research results, methodological rigour, empirical content, and impact on childhood disability care. Awards: Up to three cash prizes will be awarded. The top three candidates will be invited to present their research and compete during the annual Pursuit Award Ceremony at Holland Bloorview on May 15, 2018. Finalists may also be eligible for a prestigious post-doctoral fellowship at the Bloorview Research Institute. All travel and accommodation costs will be covered. Deadline for applications: Friday, February 2, 2018 at 5pm.
  • Mitacs Elevate: Winter 2018 (PostDoc fellowships, all disciplines) - DEADLINE UPDATED. Mitacs Elevate is a postdoctoral fellowship with a customized research management training component. Elevate fellows progress through the program in a cohort, giving them cross-disciplinary networking and peer-learning opportunities they might not have otherwise in their careers. Over the two-year fellowship, Elevate fellows divide their time between their partner organization project and university-based research with their faculty supervisor. UPDATED - UofT internal deadline: February 19, 2018; Sponsor deadline: February 21, 2018.
  • Call for International Doctoral Cluster (IDC) Applications. What is an IDC? International Doctoral Cluster is a research and doctoral education arrangement in a well-defined area/issue of research that brings together a critical mass of complementary talent (PIs, PDFs and graduate students) at U of T and partner institutions (academic/corporate/NGO etc.) in the form of an alliance that is more than the sum of its parts. The goal is to support cross-disciplinary and border collaborations to catalyze new ideas and transformational innovations. Funding model: Office of the Vice-President International (OVPI) and the School of Graduate Studies (SGS) will seed fund the associated mobility costs for U of T students, PDFs, and faculty.  OVPI and SGS will fund up to 1/3rdof the budget, generally, capped at 33,000 CAD/Year; PIs should mobilize the rest from within and beyond the University (e.g. division, Tri-Agency, industry,  philanthropy etc.). Further details here. Interested U of T faculty should collaborate with international partners to develop a 2 – 3 page proposal and submit it to OVPI. Deadline for proposals: February 1, 2018.
  • RBC Prize for Innovation and Entrepreneurship. Do you have a great idea for a company or are you already working in an innovative startup? The RBC Prize for Innovation and Entrepreneurship is an annual business pitch competition to recognize, reward and accelerate U of T’s innovative technologies and startups. Part of the Entrepreneurship@UofT Week Startup Showcase, the competition will take place Thursday, March 1st at MaRS. Selected individuals or teams will compete by showcasing their business idea via a 5-minute pitch to a panel of judges for the following prizes: Early Stage Prizes: 1st Prize $10,000; 2nd Prize $5,000. Later Stage Prizes: 1st Prize $25,000; 2nd Prize $10,000. Further information here. Deadline to apply: January 26, 2018.
  • EU Horizon 20/20, and European Research Funding Information Session. The University is pleased to invite those interested in learning more about multidisciplinary funding opportunities from the EU Horizon 20/20 program to an information session to be held at the time and location noted below.  The session will be led by Mr. Luigi de Masellis, who is the Advisor for Economic and Commercial Affairs with the Delegation of the European Union to Canada. While funding to Canadian faculty participating on Horizon 20/20 collaborations is not guaranteed, the information session will cover participation in these opportunities.  Horizon 20/20 has close to 80 billion Euros of funding available during its current mandate (2014 to 2020.)  In addition, there will be discussion about funding available for Canadian researchers for individual grants from the European Research Council, and the Marie Sklowdowska-Curie Actions. More details about the programs can be found here:  EU Horizon 20/20; European Research CouncilMarie Sklowdowska-Curie Actions.
    Date: January 26, 2018 from 10 am-12 noon
    Location: Governing Council Board Room, Simcoe Hall, Room 209 (St. George Campus
    Please RSVP to Julia Kulik, Office of the Vice-President, International Relations at julia.kulik@utoronto.ca
  • The Kidney Foundation of Canada: Allied Health Doctoral Fellowships and Scholarships 2018. The application forms  are now available on the Foundation's website. Please note the forms and guidelines have been revised. Deadline for applications: March 15, 2018.
    • Allied Health Doctoral Fellowships: The Foundation offers a limited number of fellowships designed to provide for full-time academic and research preparation at the doctoral level. The objective of this program is to promote and enhance the development of nephrology/organ donation allied health investigators in Canada. The award is for up to $31,000/year and is tenable in Canada or abroad (for programs outside Canada, the applicant must provide a statement indicating the intention to return to Canada).
    • Allied Health Scholarships: The purpose of the Allied Health Scholarship award is to assist the student with a demonstrated interest in nephrology/organ donation in pursuing education at the Masters level to promote and enhance the development of nephrology allied health investigators in Canada.
  • Huntington Society of Canada: Navigator Research Program 2018. This program supports basic scientific research of direct and immediate relevance to Huntington Disease in Canada with the aim of providing a platform for the recruitment of outstanding investigators to HD research, to facilitate research collaboration nationally and internationally, and to support research that is relevant to other neurodegenerative disorders. Deadline for Letters on Intent: February 15, 2018 at 3pm ET.
  • Prostate Cancer Foundation (PCF): Young Investigator Awards. The Prostate Cancer Foundation (www.pcf.org) champions investment in human capital to fast-forward solutions for prostate cancer with the ultimate goal of ending death and suffering from metastatic prostate cancer. We continue to focus significant efforts on developing gifted cohorts of young prostate cancer researchers and are pleased to announce a new round of funding for PCF Young Investigators. We especially seek young investigators with appointments in VA hospitals where research directly affects veterans with advanced prostate cancer. View the RFA for complete details. Deadline for submissions: March 19, 2018, at 3pm EDT.
  • Saving Lives at Birth: A Grand Challenge for Development (Grand Explorations (GCE): Saving Lives at Birth). The Sponsors are seeking groundbreaking prevention and treatment approaches for pregnant women and newborns in poor, hard-to-reach communities around the time of delivery. This is the period when the majority of maternal and newborn deaths occur and the population that has been the most difficult to reach. We seek innovative ideas that can leapfrog conventional approaches in three main domains: (1) technology; (2) service delivery; and (3) “demand side” innovation that empowers pregnant women and their families to practice healthy behaviors and be aware of and access health care during pregnancy, childbirth and the early postnatal period, especially the first two days after birth. Deadline for Expressions of Interest: February 28, 2018 at 2pm ET.
  • amfAR Impact Grants: Gaining Insights from the Clinic. The goal of this RFP is to generate practical, implementable information that will facilitate the design and interpretation of broadly generalizable HIV cure clinical research. Specific areas of interest: 1) Identify pre-ATI predictors of post-treatment control (PTC) or delay to rebound; 2) Diversify the HIV cure clinical study population. Please visit their website to view the available funding opportunities within this RFP. Registration deadline: April 6, 2018 at 12pm ET; Deadline for Letters of Intent: April 11, 2018 at 3pm ET.


January 9, 2018

  • CIHR Webinars on the Project Grant: Spring 2018 Application. CIHR is holding a series of webinars on the Project Grant: Spring 2018 application. These Question and Answer webinars are designed to complement the Project Grant: Spring 2018 Applicant Learning Module, which will be available on January 19th on the Learning for Applicants web page. Together, the module and webinars will give applicants an insightful understanding of the recent changes to the Project Grant competition and the application submission process. The Project Grant: Spring 2018 webinars will be held between January 26th and February 28th. Register for a webinar now.
    For more information, please contact the CIHR Contact Centre at: Support@cihr-irsc.gc.ca
  • CIHR Project Grant: Spring 2018 Priority AnnouncementsThe specific objective of the Project Grant: Spring 2018 Priority Announcements is to offer additional sources of funding for highly rated applications that are relevant to specific research areas. CIHR Research Priority Areas:
  • Michael Bahen Chair in Epilepsy Research at the University of Toronto. The Faculty of Medicine at the University of Toronto invites applications for the Michael Bahen Chair in Epilepsy Research. The Michael Bahen Chair in Epilepsy Research was established to support an outstanding academic individual with a demonstrated track record in research and clinical excellence within the field of epilepsy. This individual should have demonstrated success in epilepsy research and creative professional activity within epilepsy management with a particular focus on complex and/or inherited forms of epilepsy. Read more...
  • Alberta Innovates/Alberta Prion Research Institute: New Collaborations Program (New)The New Collaborations program is intended to encourage collaborations between researchers from an Alberta-based institution with researchers from institutions outside Alberta. Qualified investigators may seek funding for small research projects directly related to prion diseases and/or human neurodegenerative diseases and dementias where the etiology involves protein misfolding and the pathogenesis has prion-like characteristics. New Collaborations grants are intended to foster the development of new research partnerships by supporting short-term research projects aimed at addressing relevant fields of inquiry in the Prion Institute themes. Grants of up to $100,000 CAD for a maximum of two years are available. Deadline for proposals: Continuous.
  • Jeffrey Modell Foundation: Translational Research Program (Primary Immunodeficiency). The Jeffrey Modell Foundation encourages all investigators with the appropriate knowledge and research skill level to apply to this program. Applications submitted by investigators with vast expertise in Primary Immunodeficiency, as well as young investigators with robust scientific merit will all be considered. All international and U.S. applicants are eligible. The Foundation especially encourages investigators who are not currently receiving funding from the National Institutes of Health to apply. Upper amount: $250,000 USD over two years. Deadline for applications: February 15, 2018.
  • American Institute for Cancer Research (AICR): Research Grants. AICR's Investigator-Initiated Research Grant Program welcomes proposals for research addressing the effects of diet, nutrition, body composition, and physical activity on cancer risk and outcomes. Applications to this program must address either the Cancer Prevention or the Cancer Survivors Research Area and align with at least one of the Research Themes (Biological Mechanisms or Host Factors/Susceptibility); for research in the area of Cancer Survivors, applications are invited to address a third theme of Exposure-Outcome Relationships. Upper amount $150,000 USD over two years. Deadline for Letters of Intent: January 26, 2018. Full applications are due by May 11, 2018.
  • National Psoriasis Foundation: Sponsor deadline for all programs: January 19, 2018.
    • Pediatric Psoriasis Challenge Grants. In collaboration with the Pediatric Dermatology Research Alliance (PeDRA), the National Psoriasis Foundation (NPF) is seeking grant applications that encourage the advancement of innovative research into pediatric psoriasis. The 2018 Pediatric Psoriasis Challenge Grant will support projects that address any aspect of the disease, including the cause, diagnosis, or treatment of pediatric psoriasis and/or related comorbidities. Proposals from basic, translational, clinical, epidemiological, health services and other relevant research areas are all welcome. Upper amount $75,000 USD. 
    • Translational Research Grants: Translational Research Grants fund research initiatives that focus on the rapid translation of basic scientific discoveries into clinical applications with a clear benefit for patients with psoriatic disease. Applications related to all aspects of psoriatic disease are strongly encouraged, including basic science, translational research, technology, epidemiology, health services, and clinical research. Upper amount $200,000 USD.
    • Discovery Grants: Discovery Grants fund researchers while they explore preliminary ideas and conduct proof-of-concept experiments. The goal is to stimulate the development of new research programs in the field of psoriatic disease capable of competing for long-term funding from the National Institutes of Health or other agencies in the future. Upper amount: $75,000 USD.
  • Sarcoma Foundation of America: Research Grants. The Sarcoma Foundation of America has developed a program to provide grants to investigators interested in translational science sarcoma research. Funding is available to cover equipment and supplies in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas.In accordance with the mission of the Foundation, research involving the development of novel agents against sarcoma, or research that could potentially lead to the development of novel agents against sarcoma, is eligible for this funding. Upper amount: $50,000 USD for one year. Deadline for applications: January 31, 2018.
  • Stiftelsen Promobilia - Promobelia Foundation: Grants for Research & Development Projects. The aim of the Foundation is to promote the development of technical aids so that disabled persons can benefit from a more active life. Their task is to support research and development of technical aids as well as to ensure that those products make it through production and reach those in need. The Foundation mainly gives support for development of tools for handicapped mobility but has also supported research on the comprehension of reading and writing difficulties. The Foundation has also supported research around diseases that can lead to severe motion problems. The Foundation gives grants in the range of SEK 100,000 - 500,000 (in USD about 10,000 - 100,000). Deadline for applications: March 22, 2018.
  • NIH: Various Opportunities. Unless otherwise stated in the funding opportunity, see Standard Due Dates Schedule for deadlines for each Grant category. If you intend to apply via the University of Toronto, it is recommended you contact Krista Montgomery in Research Services at least two weeks prior to submitting an NOI or application.  For more information on NIH application and the submission process, please visit the University's Research Funding Opportunities found here.
    • Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimers Disease (R01)
    • Consequences of amyloid protein polymorphisms in Alzheimer's disease (R01)
    • Improving Implementation of Seek, Test, Treat and Retain Strategies among People Who Inject Drugs in Low to Middle Income Countries (R01)
    • Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01)
    • Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01) and (R21)
    • Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21) and (R01)
    • Self-Management for Health in Chronic Conditions (R01) and (R21)
    • Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01) and (R21)
    • Early-life Factors and Cancer Development Later in Life (R01) and (R03) and (R21)
    • Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01)
    • Advancing Basic Neurobiology Toward Translation Through Assay Development (R01)
    • Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21) and (R01) and (R03)
    • Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)
    • Human Cell Biology of Alzheimer's Disease Genetic Variants (R01)
    • Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01)
    • Basic and Translation Research on Decision Making in Aging and Alzheimer's Disease (R21) and (R01)
    • Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21) and (R01)
    • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required)
    • Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01)


Back to Top